cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer

Summary

The EpiCORE study aims to identify cfDNA-based epigenetic markers predictive of response to first-line chemotherapy (FOLFOX or FOLFIRI) in metastatic colorectal cancer (mCRC). By integrating 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiling, this study seeks to establish a non-invasive biomarker panel capable of distinguishing responders from non-responders.

Eligibility

Inclusion Criteria:

* Histologically confirmed metastatic colorectal adenocarcinoma (mCRC).
* Received first-line chemotherapy (FOLFOX or FOLFIRI).
* Availability of pre-treatment serum or plasma samples for cfDNA 5mC/5hmC analysis.
* Documented radiologic or clinical response evaluation (RECIST 1.1 or PFS-based).
* RAS/BRAF mutation status available.

Exclusion Criteria:

* Inadequate cfDNA yield or poor DNA quality.
* Non-adenocarcinoma histology.
* Active inflammatory or autoimmune disease that may alter cfDNA methylation.
* Concomitant malignancy requiring systemic therapy.

Conditions2

Locations1 site

Browse More Trials